RHEACELL GmbH & Co. KG

Quick facts

Phase 3 pipeline

• allo-APZ2-CVU
  Allo-APZ2-CVU is a small molecule that targets the CVU receptor.
• allo-APZ2-OTS · Autoimmune diseases
  Allo-APZ2-OTS is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).

Phase 1 pipeline

• allo-APZ2-DFU
• allo-APZ2-EB
• LSC2

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• RHEACELL GmbH & Co. KG portfolio CI brief
• RHEACELL GmbH & Co. KG pipeline updates RSS